Novel paradigm for treating vasculopathy in systemic sclerosis: Vascular progenitor cells and statins

Current Rheumatology Reports

Volumn 9, Issue 1, 2007, Pages 1-3

  Hinchcliff, Monique ^b   Varga, John ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CD133 ANTIGEN; CD34 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PENTOXIFYLLINE; PRAVASTATIN; PROTON PUMP INHIBITOR; VASCULOTROPIN;

ANGIOGENESIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; DRUG TOLERABILITY; ENDOTHELIUM CELL; HUMAN; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; NOTE; PATHOGENESIS; RAYNAUD PHENOMENON; STEM CELL; SYMPATHECTOMY; SYSTEMIC SCLEROSIS; THROMBOCYTE AGGREGATION; VASCULAR DISEASE;

ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOVASCULARIZATION, PHYSIOLOGIC; PILOT PROJECTS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; STEM CELLS;

EID: 34249328135     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0014-1     Document Type: Note

References (12)

1. Abraham DJ, Varga J: Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005, 26:587-595.
2. Denton CP, Black CM: Targeted therapy comes of age in scleroderma. Trends Immunol 2005, 26:596-602.
3. Murasawa S, Asahara T: Endothelial progenitor cells for vasculogenesis. Physiology (Bethesda) 2005, 20:36-42.
4. Clancy RM: Preventing and repairing vascular damage in scleroderma: should we focus beyond vasodilatation to recruitment of endothelial precursor cells? Arthritis Rheum 2006, 54:1730-1732.
5. Simons M: Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed? J Am Coll Cardiol 2005, 46:835-837.
6. Kuwana M, Okazaki Y, Yasuoka H, et al.: Defective vasculogenesis in systemic sclerosis. Lancet 2004, 364:603-610.
7. Distler O, Del Rosso A, Giacomelli R, et al.: Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002, 4:R11.
8. Bonetti PO, Lerman LO, Napoli C, Lerman A: Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 2003, 24:225-248.
9. Llevadot J, Murasawa S, Kureishi Y, et al.: HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001, 108:399-405.
10. Furukawa S, Yasuda S, Amengual O, et al.: Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann Rheum Dis 2006, 65:1118-1120.
11. Kuwana M, Kaburaki J, Okazaki Y, et al.: Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum 2006, 54:1946-1951.
12. Derk CT, Jimenez SA: Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? Autoimmun Rev 2006,5:25-32.